# Tafasitamab

Source: https://onco.cc/drugs/tafasitamab/  
OnCo record `tafasitamab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A CD19 antibody given with lenalidomide for lymphoma patients who cannot have a transplant; in 2026 it showed the first frontline gain over R-CHOP in high-risk disease.

## Summary

L-MIND (single arm, with lenalidomide): ORR 60%, CR 43%, median DOR ~44 months; accelerated approval July 2020 for transplant-ineligible R/R DLBCL. frontMIND phase 3 (Lancet 2026): tafasitamab + lenalidomide + R-CHOP vs placebo + R-CHOP in IPI 3-5 DLBCL; 2-year PFS 71.1% vs 62.9%, HR 0.75; OS immature (HR 0.85). Also approved 2025 with lenalidomide-rituximab in follicular lymphoma (inMIND).

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-07
- Brand: Monjuvi
- Modality: Monoclonal antibody (anti-CD19, Fc-enhanced)
- Mechanism: Fc-engineered (XmAb) anti-CD19 antibody with enhanced ADCC/ADCP; lenalidomide augments NK activity.
- Approvals: US 2020: R/R DLBCL with lenalidomide, transplant-ineligible (accelerated); US 2025: R/R follicular lymphoma with lenalidomide and rituximab; EU 2021: EU brand Minjuvi
- Dosing: IV; 12 mg/kg days 1, 8, 15, 22 of cycles 1-3, then days 1 and 15 from cycle 4; lenalidomide 25 mg days 1-21 for up to 12 cycles, tafasitamab until progression
- Toxicity (grade 3+): Neutropenia 48%; Thrombocytopenia 17%; Febrile neutropenia 12%

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Tafasitamab
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tafasitamab

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/)
- companies: [Incyte](https://onco.cc/companies/incyte/), [MorphoSys (Novartis)](https://onco.cc/companies/morphosys/)
- terms: [ADCC (antibody-dependent cellular cytotoxicity)](https://onco.cc/terms/adcc/), [What the NHS in England funds for lymphoma, appraisal by appraisal](https://onco.cc/terms/lymphoma-tx-uk-access/)
- trials: [A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa](https://onco.cc/trials/nct04680052/), [A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No](https://onco.cc/trials/nct03930953/), [Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab](https://onco.cc/trials/nct06465433/), [frontMIND](https://onco.cc/trials/frontmind/), [L-MIND](https://onco.cc/trials/l-mind/), [Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients](https://onco.cc/trials/nct05222555/), [Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (](https://onco.cc/trials/nct05429268/), [To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL](https://onco.cc/trials/nct04661007/)
- key papers: [Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial](https://onco.cc/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)
- biomarkers: [CD19 expression (CD19-positive)](https://onco.cc/biomarkers/cd19-expression/)

---
JSON: https://onco.cc/api/v1/entities/tafasitamab.json